Multimodality Imaging to Detect Anthracycline-induced Cardiotoxicity in Breast Cancer Patients: A Mechanistic Pilot Study (The MIDAC Study)

Background: Anthracycline-induced cardiotoxicity remains highly prevalent among cancer patients undergoing chemotherapy and its pathophysiology remains poorly understood. Objective: In the Multimodality Imaging to Detect Anthracycline-induced Cardiotoxicity (MIDAC) study, the aim was to use hybrid cardiac PET/MRI to provide mechanistic insights into the pathophysiology of anthracycline-induced cardiotoxicity. Methods: Seventeen female breast cancer patients scheduled for doxorubicin chemotherapy were prospectively recruited to undergo serial cardiac imaging at baseline (PET/MRI), 3 months (PET/MRI) and 12 months post-chemotherapy (MRI only). Results: Compared to baseline, at 3 months there was: a reduction in left ventricular ejection fraction (57 ± 6% versus 62 ± 4%; p<0.001); a reduction in both global circumferential and longitudinal strain (global circumferential strain and global longitudinal strain); higher native myocardial T1 values (1,304 ± 35 versus 1,260 ± 51 ms; p=0.004); increased extracellular volume fraction (29 ± 3% versus 26 ± 3%; p=0.012); a reduction in intracellular mass (44 ± 7 versus 47 ± 8 g; p=0.03); and a reduction in standardised uptake values of fluorine-18 fluorodeoxyglucose uptake (4.2 ± 2.3 versus 6.2 ± 2.6; p=0.012). There was a positive correlation between relative standardised uptake values reductions and global longitudinal strain at 3 months (R 0.54, p=0.032). At 12 months, left ventricular ejection fraction remained lower than baseline (56 ± 6% versus 62 ± 4%; p<0.001) with an associated reduction in global circumferential strain and global longitudinal strain. Native myocardial T1 values remained higher than baseline but with no significant differences in T2, intracellular mass and extracellular volume fraction. Conclusion: Observations at 3 months post-doxorubicin chemotherapy were diffuse interstitial fibrosis, a reduction in intracellular mass, and a reduction in myocardial glucose metabolism; changes which were associated with a reduction in global longitudinal strain and left ventricular ejection fraction. Diffuse interstitial fibrosis persisted at 12 months and was associated with lower left ventricular ejection fraction and global longitudinal strain.

Authors

Institutions

Publication Details

Journal
Journal of Asian Pacific Society of Cardiology
Published
2025-10-23
DOI
https://doi.org/10.15420/japsc.2025.05
Primary Topic
Chemotherapy-induced cardiotoxicity and mitigation
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Multimodality Imaging to Detect Anthracycline-induced Cardiotoxicity in Breast Cancer Patients: A Mechanistic Pilot Study (The MIDAC Study)

Samuel G.W. Ow, Derek J. Hausenloy, John J. Totman, Jennifer Bryant et al.
Journal of Asian Pacific Society of Cardiology
Chemotherapy-induced cardiotoxicity and mitigation
article

Multimodality Imaging to Detect Anthracycline-induced Cardiotoxicity in Breast Cancer Patients: A Mechanistic Pilot Study (The MIDAC Study)

Samuel G.W. Ow, Derek J. Hausenloy, John J. Totman, Jennifer Bryant, Yiying Han, Soo Chin Lee, Mary C. Stephenson, Heerajnarain Bulluck, Jun Hua Chong, Stéphanie Marchesseau, Jim O’Doherty, Liang Zhong, Shuang Leng, Andrea Li-Ann Wong
article en

Abstract

Background: Anthracycline-induced cardiotoxicity remains highly prevalent among cancer patients undergoing chemotherapy and its pathophysiology remains poorly understood. Objective: In the Multimodality Imaging to Detect Anthracycline-induced Cardiotoxicity (MIDAC) study, the aim was to use hybrid cardiac PET/MRI to provide mechanistic insights into the pathophysiology of anthracycline-induced cardiotoxicity. Methods: Seventeen female breast cancer patients scheduled for doxorubicin chemotherapy were prospectively recruited to undergo serial cardiac imaging at baseline (PET/MRI), 3 months (PET/MRI) and 12 months post-chemotherapy (MRI only). Results: Compared to baseline, at 3 months there was: a reduction in left ventricular ejection fraction (57 ± 6% versus 62 ± 4%; p<0.001); a reduction in both global circumferential and longitudinal strain (global circumferential strain and global longitudinal strain); higher native myocardial T1 values (1,304 ± 35 versus 1,260 ± 51 ms; p=0.004); increased extracellular volume fraction (29 ± 3% versus 26 ± 3%; p=0.012); a reduction in intracellular mass (44 ± 7 versus 47 ± 8 g; p=0.03); and a reduction in standardised uptake values of fluorine-18 fluorodeoxyglucose uptake (4.2 ± 2.3 versus 6.2 ± 2.6; p=0.012). There was a positive correlation between relative standardised uptake values reductions and global longitudinal strain at 3 months (R 0.54, p=0.032). At 12 months, left ventricular ejection fraction remained lower than baseline (56 ± 6% versus 62 ± 4%; p<0.001) with an associated reduction in global circumferential strain and global longitudinal strain. Native myocardial T1 values remained higher than baseline but with no significant differences in T2, intracellular mass and extracellular volume fraction. Conclusion: Observations at 3 months post-doxorubicin chemotherapy were diffuse interstitial fibrosis, a reduction in intracellular mass, and a reduction in myocardial glucose metabolism; changes which were associated with a reduction in global longitudinal strain and left ventricular ejection fraction. Diffuse interstitial fibrosis persisted at 12 months and was associated with lower left ventricular ejection fraction and global longitudinal strain.

Journal of Asian Pacific Society of CardiologyVol. 4
National University of Singapore (SG), Leeds Teaching Hospitals NHS Trust (GB), National University Cancer Institute, Singapore (SG), National University Heart Centre Singapore (SG), National Heart Centre Singapore (SG), National Centre for Infectious Diseases (SG)
Amgen, Eli Lilly and Company, Pfizer, AstraZeneca, Duke-NUS Medical School, Aromatic Plant Research Center, Eisai, Novo Nordisk, Servier, Medical Research Council, National Medical Research Council
Openalex Percentile: Top 53%
Chemotherapy-induced cardiotoxicity and mitigation
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.